The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol
Womack J, Leblanc M, Sager A, Zaets L, Maisto S, Garcia A, Aoun-Barakat L, Brown S, Edelman E, Fiellin D, Fisher J, Fraenkel L, Kidwai-Khan F, Marconi V, Martino S, Pulk R, Satre D, Virata M, Justice A, Hsieh E. The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol. AIDS And Behavior 2024, 1-15. PMID: 39465468, DOI: 10.1007/s10461-024-04533-6.Peer-Reviewed Original ResearchUnhealthy alcohol useAlcohol usePharmacist-delivered interventionVeterans Aging Cohort StudyPilot study protocolStudy protocolElectronic health recordsSupport behavior changePre-test/post-test designAging Cohort StudySelf-administered surveyAlcohol use disorderAlcohol Research CenterBothersome symptomsPre-test/post-testCommunicating riskHealth recordsLong-term medicationHealth symptomsCounseling interventionCounseling sessionsSessions 2 weeksQualitative interviewsAlcohol consumptionUse disorderIntegrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial.
Edelman E, Dziura J, Deng Y, DePhilippis D, Ferguson T, Brown S, Marconi V, Goetz M, Rodriguez-Barradas M, Simberkoff M, Molina P, Weintrob A, Maisto S, Paris M, Justice A, Bryant K, Fiellin D. Integrated stepped alcohol treatment with contingency management for unhealthy alcohol use among people with HIV: A randomized controlled trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024 PMID: 39321757, DOI: 10.1097/qai.0000000000003534.Peer-Reviewed Original ResearchUnhealthy alcohol useSelf-reported abstinenceAlcohol useLost to follow-upContingency managementAlcohol use disorderRandomized controlled trialsSubstance use treatmentAlcohol abstinenceFollow-upUse disorderControlled trialsPWHAlcohol treatmentAbstinenceUse treatmentEvidence of abstinenceHIVWeeksMean proportionTreatmentTrialsAlcoholDaysParticipantsS96 The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings
Homsted F, Gardner T, Nesin N, McGrady F, Fiellin D, Joudrey P, McLeman B, Gauthier P, Moore S, Marsch L, Ghitza U, Rao D. S96 The Pharmacist-Integrated Medication Treatment for Opioid Use Disorder (PrIMO) Model: Operationalizing an Effective Clinical Care Model to Assess Feasibility in Diverse Care Settings. Drug And Alcohol Dependence 2024, 260: 110207. DOI: 10.1016/j.drugalcdep.2023.110207.Peer-Reviewed Original ResearchExtended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
D’Onofrio G, Herring A, Perrone J, Hawk K, Samuels E, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall M, Walsh S, Dziura J, Fiellin D. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Network Open 2024, 7: e2420702. PMID: 38976265, PMCID: PMC11231806, DOI: 10.1001/jamanetworkopen.2024.20702.Peer-Reviewed Original ResearchConceptsClinical Opiate Withdrawal ScaleExtended-release buprenorphineOpioid use disorderPrecipitated withdrawalOpioid withdrawalOpioid use disorder treatmentCow scoreClinical Opiate Withdrawal Scale scoreAdverse eventsNonrandomized trialsSevere opioid use disorderDays of opioid useOpiate Withdrawal ScaleModerate to severe opioid use disorderFormulation of buprenorphineOpioid use disorder careWithdrawal ScaleUse disorderAssociated with medicationsNonprescribed opioidsPain scoresExtended-releaseInjection painOpioid useAdult patientsBuprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
Balter D, Puglisi L, Dziura J, Fiellin D, Howell B. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial. Journal Of Substance Use And Addiction Treatment 2024, 164: 209438. PMID: 38857827, PMCID: PMC11300157, DOI: 10.1016/j.josat.2024.209438.Peer-Reviewed Original ResearchXR-NTXBuprenorphine-naloxoneOpioid use disorderCriminal legal involvementUse disorderHazard of overdoseLifetime incarcerationLegal involvementOpioid use disorder treatment outcomesPer-protocol analysisExtended-release naltrexoneMOUD effectivenessTreatment outcomesEffects of medicationHazard of relapseSecondary analysisIntention-to-treat analysisIntention-to-treatRandomized controlled trialsEffects of MOUDRelapseControlled trialsDisordersOpioidPotential effect modifiersStepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain.
Rossi R, Cutter C, Beitel M, Covelli M, Fiellin D, Kerns R, Vassilieva S, Olabisi D, Barry D. Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain. Substance Use & Addiction Journal 2024, 29767342241245095. PMID: 38606900, PMCID: PMC11470109, DOI: 10.1177/29767342241245095.Peer-Reviewed Original ResearchTreatment-as-usualOpioid use disorderChronic painCognitive behavioral therapyStepped careNonmedical opioid useEffectiveness trialOpioid useAlcohol useSession of exerciseStepped care modelWeekly group sessionsPain-related outcomesStress reductionDecreased pain intensityUse disorderNational Institutes of HealthOpioid use disorder treatmentCare modelInstitutes of HealthAssociated with higher levelsPain intensityPilot study of patientsPain improvementDurability of treatment responseImplementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations
McLeman B, Gauthier P, Lester L, Homsted F, Gardner V, Moore S, Joudrey P, Saldana L, Cochran G, Harris J, Hefner K, Chongsi E, Kramer K, Vena A, Ottesen R, Gallant T, Boggis J, Rao D, Page M, Cox N, Iandiorio M, Ambaah E, Ghitza U, Fiellin D, Marsch L. Implementing a pharmacist-integrated collaborative model of medication treatment for opioid use disorder in primary care: study design and methodological considerations. Addiction Science & Clinical Practice 2024, 19: 18. PMID: 38500166, PMCID: PMC10949656, DOI: 10.1186/s13722-024-00452-y.Peer-Reviewed Original ResearchConceptsStages of Implementation CompletionPrimary care sitesOpioid use disorderCare sitesConsolidated Framework for Implementation ResearchPatient electronic health record dataCollaborative model of careTreatment of opioid use disorderElectronic health record dataPrimary care teamsCollaborative care modelModels of careHealth record dataOpioid use disorder careUse disorderImplementation facilitatorsCare modelCare teamPrimary careImplementation researchDiscussionThis studyDispensed medicationsPharmacy techniciansInterpretation of findingsImplementation Completion